Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.55 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.55 |
| ▸ | CTSA | P10619 | 2/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.46 |
| ▸ | FNTB | P49356 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14767904 | 0.89 | CTSA (0.47) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL18228755 | 0.87 | TACR1 (0.58) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL18228875 | 0.87 | TACR1 (0.58) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL18228863 | 0.87 | TACR1 (0.58) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL8674095 | 0.86 | MEN1 (0.54) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL14691472 | 0.84 | MEN1 (0.54) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL6002264 | 0.83 | GABBR2 (0.58) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL15614165 | 0.83 | GABBR2 (0.58) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| SCHEMBL8922507 | 0.83 | CASR (0.52) | MEN1KMT2ACACNA2D1CACNA1BCACNB1 | |
| 3,3-Diphenylpropanoic Acid SCHEMBL5283373 | 0.82 | GABBR2 (0.59) | CACNA2D1CACNA1BCACNB1CACNA1CHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531653-B | Novel difluoroketoamide derivatives | 豪夫迈·罗氏有限公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3294718-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| EP-3294718-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| EP-3262026-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-10428108-B2 | Difluoroketamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428108-B2 | Difluoroketamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-9980929-B2 | Trifluoromethylpropanamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3294718-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-03-21 | — | — | EP | disclosed |
| US-20180057526-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057526-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180057526-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2016180751-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180751-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-17 | — | — | WO | disclosed |
| US-5599966-A | SUITABLE FOR TREATMENT OF DISEASES OF RESPIRATORY PASSAGES | BYK NEDERLAND BV (NL) | 1997-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348257-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES | PRMT7, GFRA3, PRMT5 | MEN1 2006/4885KMT2A 768/4885CACNA2D1 3440/4885 |
| US-20180057526-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES | PRMT9, CDK9, FLT3 | MEN1 1180/4885KMT2A 283/4885CACNA2D1 4144/4885 |
| US-10428108-B2 | Difluoroketamide derivatives | PRMT9, CDK9, FLT3 | MEN1 1193/4885KMT2A 188/4885CACNA2D1 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.